SMA Peg denied as not medically necessary by Anthem?

Anthem's specific coverage criteria for sma peg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied This Claim — and Why It's Appealable

A medical-necessity denial for a pegylated SMA therapy means Anthem's reviewer concluded that the clinical documentation submitted did not establish that the treatment meets the plan's definition of medically necessary care. In SMA, where disease course varies substantially by genetic subtype and age of onset, this denial frequently reflects a documentation gap rather than a true absence of clinical need. Assembling a complete, criteria-mapped clinical package reverses these denials at a high rate — particularly in external review.

## Your Federal Appeal Rights

Under ACA §2719, you have the right to a full internal appeal and then an independent external review through an IRO outside Anthem's control. For employer plans, ERISA §503 provides the full-and-fair-review standard. The external review request window is generally four months from the denial date. If disease progression is occurring and delay would cause serious harm, expedited external review (typically resolved within 72 hours) is available upon physician certification.

## Concrete Appeal Steps

1. Obtain the full denial rationale — Anthem must state the specific clinical criteria it found unmet. Request the applicable coverage/medical policy document. 2. Audit the original submission against Anthem's criteria — identify exactly which elements of documentation were missing or insufficient. 3. Compile the complete clinical package (see below) and file the Level 1 internal appeal within the timeframe stated on the EOB. 4. Escalate to external review if Level 1 is upheld; IRO physicians reviewing neuromuscular cases apply clinical-evidence standards independently of insurer policy. 5. Request expedited review if the prescribing physician can certify that delay endangers the patient.

## Documentation to Gather

• Diagnosis confirmation: Genetic test report confirming SMA type and copy number; specialist notes documenting functional status, disease trajectory, and current clinical presentation.
• Prior treatment history: Chronological list of all prior SMA therapies with initiation dates, durations, and documented clinical responses or reasons for discontinuation.
• Clinical severity: Pulmonary function data, motor function assessment scores described qualitatively, nutritional status, and any acute events — all from the treating clinician's chart notes.
• Prescriber medical-necessity letter: A detailed, individualized letter from the treating neurologist or neuromuscular specialist explaining why this therapy is medically necessary for this patient, referencing the FDA-approved prescribing information and the applicable guideline organization (e.g., AAN, SMA-focused specialty guidance), and directly addressing each of Anthem's stated criteria.
• Supporting specialist documentation: If relevant, letters or notes from pulmonology, physiatry, or other involved specialists corroborating the overall clinical picture.

## Criteria-Mapping Structure

Create a two-column table: left column lists each of Anthem's medical-necessity criteria verbatim from the policy; right column provides the specific chart note, test result, or prescribing-information section that satisfies each criterion. This is the single most effective format for both internal reviewers and IRO physicians.